The recipient of the inaugural global research grant will harness AI to uncover insights that could result in more personalized care for women diagnosed with ovarian cancer.

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Mayo Clinic researchers say they have discovered that ovarian cancer cells can quickly activate a survival response after treatment with PARP inhibitors.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. In addition to a recently finalized phase 1/2a trial in colorectal cancer, ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...

FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...

Avmapki Fakzynja is a type of targeted medicine called a tyrosine kinase inhibitor (TKI). TKIs are used to treat many different types of cancers, including ovarian cancer. Avmapki Fakzynja is ...

Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a ...

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Global Ovarian Cancer Research Consortium awarded its inaugural AI Accelerator Grant to an international research team studying whether artificial ...